Ness Technologies, Inc. (NASDAQ: NSTC and TASE: NSTC), a global provider of information technology solutions and services, announced today the start of an Oracle(R) E-Business Suite implementation at Teva Czech Industries s.r.o., a provider of pharmaceutical products. The new system will handle financial and logistics issues, replacing a current QAD MFG/Pro system. The project, which is valued at $2 million, is targeted to go into production on January 1, 2011. Ness will support the project through the end of April 2011. Teva Czech Industries is part of Teva Pharmaceutical Industries, a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients.
Teva Pharmaceutical Industries selected Ness, a leading provider of IT services and solutions in Central and Eastern Europe, an Oracle Platinum Partner and one of the region's leaders in the manufacturing segment, based on its reputation as a reliable and proven partner who could completely fulfill Teva's expectations regarding the new enterprise system. Key factors for Teva were Ness' experience in similar international projects, its professional approach and its large team of dedicated Oracle E-Business Suite experts in Central and Eastern Europe.
"Our company is strongly export focused, exporting over 80% of our production, including to the highly complex markets in the U.S. and Western Europe," said Jiri Urbanec, CEO of Teva Czech Industries. "Thanks to the launch of a new plant for solid pharmaceutical drugs this year, we expect that our exports will increase more than three times. In order to produce four billion tablets annually for one of the toughest markets in the world, we need to manage our financial and logistics processes with world-class tools. The new system will not only simplify and optimize Teva's production plant in Opava, Czech Republic, and its commercial units in Prague, Czech Republic, and Bratislava, Slovakia, but it will also connect the two European countries to the Israeli offices of its parent company, Teva Pharmaceutical Industries."